Amferia has completed a €1.2M investment round to advance its clinical development and launch new antimicrobial healthcare solutions targeting human health.
Agneta Edberg expressed gratitude towards both existing and new investors for supporting Amferia's vision to combat resistant antimicrobial infections globally.
CEO Anand Rajasekharan highlighted the potential of bacterial infections to become the leading cause of death due to antibiotic resistance, emphasizing the importance of their hydrogel technology.
Rajasekharan noted that their approach utilizes antimicrobial peptides that mimic the immune system, reducing reliance on traditional antibiotics.
Collection
[
|
...
]